The U.S. Food and Drug Administration (FDA) has approved Abbott’s request to expand the magnetic resonance imaging (MRI) compatibility with its Proclaim XR spinal cord stimulation system with Octrode leads, which is used to manage chronic pain. The decision lifts previous restrictions for Octrode lead tip location and the amount of radiofrequency power that could be used during an MRI scan. “MRIs have increasingly become an important tool helping doctors diagnose an illness or injury.…

You must be logged in to read/download the full post.